Oxycodone, an option in pain management since 1917 (14 hidroxi-7,8- dehydrocodeinone);Oxicodona, una opción en el manejo del dolor desde 1917 (14 hidroxi-7,8-dehidrocodeinona)

Medicina Paliativa

Volumn 11, Issue 4, 2004, Pages 246-263

  Domínguez Castillejos, Gloria ^a   Gomez Sancho M ^b   Verd, M ^c   Brennan Bourdon, L J ^c  

^a UNIVERSIDAD AUTÓNOMA DE GUADALAJARA   (Mexico)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c Medical Research Division   (Mexico)

Author keywords

Cancer pain management; Kappa receptor opioid agonist; Opioids; Pain management; Pure opioid

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BUPRENORPHINE; BUTORPHANOL; CODEINE; DIHYDROMORPHINE; FLUOXETINE; HYPNOTIC AGENT; KAPPA OPIATE RECEPTOR; KETOCONAZOLE; LEVORPHANOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR; MUSCLE RELAXANT AGENT; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; PHENOTHIAZINE DERIVATIVE; QUINIDINE; RIFAMPICIN; RITONAVIR; SEDATIVE AGENT; THEBAINE; TRANQUILIZER; UNINDEXED DRUG;

ANALGESIC ACTIVITY; ASTHENIA; CANCER PAIN; COMA; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG RELEASE; DRUG STRUCTURE; HUMAN; HYPOTENSION; NAUSEA; OSTEOARTHRITIS; PAIN; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRURITUS; RESPIRATION DEPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUSTAINED RELEASE PREPARATION; VERTIGO; VOMITING; XEROSTOMIA;

EID: 12844288916     PISSN: 1134248X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Dermot R. Fitzgibbon-Cancer pain management. Bonicás management of pain Ed. Lippincott W and W 2001. p. 659.
2. Guía clínica Práctica No. 9. Manejo del dolor por cáncer. Departament of Health and Human Services. U.S., 1994.
3. Ripamonti C, Dickerson D. Strategies for the treatment of cancer pain in the New Millennium. Drugs 2001; 61 (7): 955-77.
4. Mucci-LoRusso P, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. European Journal of Pain 1998; 2(2): 239-49.
5. Kaiko RF, et al. Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone. Clinical Pharmacology and Therapeutics 1996: 59(1): 52-61.
6. Levy MH. Avance de la analgesia opioide con oxicodona de liberación controlada 2001; 5 (Supl. A): 113-6.
7. Glare PA, Walsh TD. Dose-ranging study of Oxycodone for chronic pain in advanced cancer. J Clin Oncol 1993; 11: 973-8.
8. Kalso E, Vaino A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639-46.
9. Joranson DE, Cleeland CS, Weissman DE, et al. Opioids for chronic cancer and non-cancer pain: a survey of state medical board members. Federation Bulletin: J Med Licensure Discipline 1992; 79 (4): 15-49.
10. Larue F, Colleau SM, Fontaine AL, et al. Oncologist and primary care physicians attitudes toward pain control and morphine prescribing in France. Cancer 1995; 76: 2375-82.
11. Zenz M, Willweber-Strumpf A. Opiophobia and cancer pain in Europe. Lancet 1993; 341: 1075-6.
12. Inturrisi CE. Clinical pharmacology of opioids for pain. The Clinical Journal of Pain 2002; 18: S3-S13.
13. Parr RB. Using controlled-release oxycodone for the management of chronic cancer and non-cancer pain. American Pain Society 1996; 6 (4): 6.
14. Shah S, Hardy J. Oxycodone: a review of the literature. European J of Pall Care 2001; 8 (3): 93-6.
15. Pöyhiä R, Vainio A, Kalso E. A review of oxycodone's clinical pharmacokinetics and pharmacodynamics. Journal of Pain and Symptom Management 1998; 8 (2): 63-7.
16. Baselt RC, Gravey RH. Disposition of toxic drugs and chemicals in man; 3rd ed. Chicago: Year Book Medical, 1989. p. 626-7.
17. Plummer JL, Cmielewski PL, Reynolds GD, Gourlay GK, Cherry DA. Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain 1990; 40: 339-347.
18. Pöyhiä R, Seppälä R, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617-21.
19. Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clinical Therapeutics 1996; 18 (1): 95-105.
20. Cairns R. The use of oxycodone in cancer-related pain: a literature review. International Journal of Palliative Nursing 2001; 7 (11): 523-7.
21. Evans PJD. Controlled-release oxycodone: do we need another opiate analgesic? European J Pain 1999; 3: 67-8.
22. Sunshine A, et al. Onset and duration of analgesia for controlled-release vs. immediate-release oxycodone alone and in combination with acetaminophen in postoperative pain. Clinical Pharmacology and Therapeutics 1995; 57 (2): 137, PI-7.
23. Kalso E, Vainio A, Mattila MJ, et al. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radiorreceptor assays. Pharmacol toxicol 1990; 67: 332-402.
24. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165-71.
25. Cherny NI. The management of cancer pain. Cancer J Clinicians 2000; 50 (2): 70-116.
26. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
27. Wallestein SL, Houde RW. The clinical evaluation of analgesic effectiveness. In: Ehrenpreis, Seymour, Neidle, Amos, eds. Methods in narcotics research. New York: Marcel Dekker, 1975. p. 127-45.
28. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
29. Kaiko RF, Benziger D, Cheng C, Hou Y, Grandy R. Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine. Clin Pharmacol Ther 1996; 59: 130.
30. Houde RW. The use and missuse of narcotics in the treatment of chronic pain. Adv Neurol 1974; 4: 527-36.
31. deWit R, Van Dan P, Vielroye-Kerkmeer A, et al. The treatment of chronic cancer pain in a cancer hospital in the Netherlands. J Pain Symptpm Manage 1999; 17 (5): 333-50.
32. Cancer Pain: a monograph on the management of cancer pain (h42-2/5). Ottawa Canada: Health and Welfare Canada. Minister of supply and services, 1984.
33. Plummer JL, Cmielewski PL, Reynolds GD, Gourlay GK, Cherry DA. Influence of polarity on dose-response relationships of intrathecal opioides in rats. Pain 1990; 40: 339-47.
34. Heiskanen TE, Ruismäki PM, Seppälä TA, Kalso EA. Morphine or oxycodone in cancer pain? Acta Oncológica 2000; 39: 941-7.
35. Leow KP, Crammond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxicodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995; 80: 296-302.
36. Leow E, Pöyhiä R, Onnela P, Linko K, et al. Oxycodone and morphine in postoperative pain. Acta Anaesthesiol. Scand 1991; 35: 642-6.
37. De Boer AG, de Leede IGJ, Breimer DD. Drug absorption by sublingual and rectal routes. Br J Anaesth 1984; 56: 69-82.
38. Van Hoogdalem EW, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, part I. General considerations and clinical applications of centrally acting drugs. Clin Pharmacokinetic 1991; 21: 11-26.
39. Moolenaar F, Stuurman-Benz AGG, Visser J, Huizinga T. Biopharmaceutics of rectal administration of drugs in man. Introduction of benzoic acid as a test drug. Int J Pharm 1978; 1: 323-36.
40. Moolenaar F, Yska JP, Visser J, Meijer DKF. Drastic improvement in the rectal absorption profile of morphine in man. Eur J Clin Pharmacol 1985; 29: 119-21.
41. Cole L, Hanning CD. Review of rectal use of opioids. J Pain Symptom Manage 1990; 5: 118-26.
42. Van Hoogdalem EJ, de Boer AG, Breimer DD. Pharmacokinetics of rectal drug administration, Part II. Clinical applications of peripherally acting drugs, and conclusions. Clin Pharmacokin 1991; 21: 110-28.
43. Jonson T, Christensen CB, Jordening H, Frolund C. The bioavailability of rectally administered morphine. Pharmacol Toxicol 1988; 62: 2003-5.
44. Takala A, Kaasalainen V, et al. Pharmacokinetic comparison of intravenous and intranasal administration of Oxycodone. Acta Anaesthesiol Scand 1997; 41: 309-12.
45. Cool WM, Kurtz NM, Chu G. Transnasal delivery of systemic drugs. Adv Pain Res Ther 1990; 14: 241-58.
46. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997; 73: 37-45.
47. Heiskanen T, Klaus T, et al. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol and Ther 1998; 603-11.
48. Ishida T, Oguri K, Yoshimura H. Determination of oxycodone metabolites in urines and feces of several mammalian species. J Pharmacobiodyn 1982; 5: 521-5.
49. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM. Inhibitions by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401-9.
50. Beaver WT, Wallestein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer: II comparisons of intramuscular oxycodone with intramuscular morphine and codeine J Pharmacol Exp Ther 1978; 207: 101-8.
51. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165-71.
52. Leow KP, Smith MT. The antinociceptive potencies of Oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats. Life Sci 1994; 54: 1229-36.
53. Davis M, Tailcock A. Modified-release opioids. European J of Palliative Care 2001; 8 (4): 142-6.
54. Kaido RF. Pharmacokinetics and pharmacodynamics of controlled-release opioids. Acta Anaesthesiol Scand 1997; 41: 166-74.
55. Madema JW, Kaiko R, et al. Br J Clin Pharmacol. 1996; 42 (6): 747-56.
56. Reder R, Oshlack B, et al. Steady state bioavailability of controlled-release oxycodone in normal subjets. Clin Ther 1996; 18 (1): 95-105.
57. Kirvella M, et al. The pharmacokinetics of Oxycodone in uremic patients undergoing renal transplantation. J Clin Anesth 1996; 8 (1): 13-8.
58. Tallgbren M, Olkolla KT, et al. Pharmacokinetics and ventilatory effects of oxycodone before and after liver transplantation. Clin Pharmacol Ther 1997; 61 (6): 655-61.
59. Citron ML, Kaplan R, et al. Long term administration of controlled-release Oxycodone tablets for the treatment of cancer pain. Cancer Investigation 1998; 16 (8): 562-71.
60. Houde RW. The use and misuse of narcotics in the treatment of chronic pain. Adv Neur 1974; 4: 527-36.
61. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled and immediate release oral oxycodone in cancer pain patients. J Clin Pharm 2001; 41: 500-6.
62. Makin M. Strong opioids for cancer pain. J R Soc Med 2001; 94: 1-21.
63. Hagen NA, Najib B. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997; 79 (7): 1428-37.
64. Sindrup S, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999; 83: 389-400.
65. Chan PSL, Clark AJ. Postherpetic neuralgia: Review of treatment modalities. Pain Res Manage 2000; 5(1): 69-74.
66. Dellemijn P. Are opioids effective in relieving neuropathic pain? Pain 1999; 80 (3): 453-62.
67. Pappagallo M, Raja SN, Hawthornwaite JA, Clark M, Campbell JA. Oral opiods in the management of postherpetic neuralgia: a prospective survey. Analgesia 1994; 1: 51-5.
68. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2001; 36 (7): 877-82.
69. Armer S, Meyerson BA. Lack of effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 33: 11-23.
70. Watson PN, Babul N. Efficacy of oxycodone in neuropathic pain a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837-41.
71. Johnson RW. Current and future management of herpes zoster. Antiviral Chem Chemother 1997; 8 (Supl. 1): 11-20.
72. Kanazi GE, Johnson RW, Dworkin RH. Treatment of posherpetic neuralgia: an update. Drugs 2000; 59 (5): 1113-26.
73. Zochodne DW, Max MB. An old acquaintance: opioids in neuropathic pain. Neurology 2003; 60 (6): 894-5.
74. Gimbel JS, Richards P, Porteney RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003; 60 (6): 1-8.
75. Peter C, Watson N. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000; 16(2 Supl.): 549-55.
76. Sunshine A, Olson NZ, Solon A, Rivera J, et al. Analgesic efficacy of controlled release oxycodone in postoperative pain. J Clin Pharmacol 1996; 36: 595-603.
77. Backlund M, et al. Comparison of epidural morphine and oxycodone for pain after abdominal surgery. J Clin Anesth 1997; 9 (1): 30-5.
78. Leino K, Nunes PV, Pikänen J, Vanakoski J, Takala J. The effect of sedation on weaning following coronary artery bypass grafting: propofol versus oxycodone-thiopental. Acta Anaesthesiol Scand 2000; 44: 369-77.
79. Levänen J. Ketamine and oxycodone in the management of postoperative pain. Military Medicine 2000; 165: 450-6.
80. Silvasti M, Tarkilla P, et al. Efficacy and side effects of tramadol versus oxycodone for patient-controlled analgesia after maxillofacial surgery. Eur J Anaesthesiol 1999; 16(12): 834-9.
81. Sunshine A, et al. Ketoprofen acetaminophen plus oxycodone and acetaminophen in the relief of postoperative pain. Clin Pharmacol. 1993; 54 (5): 546-55.
82. Anonymous. Oxycodone/Ibuprofen. Drugs 2001; 3 (1): 56-7.
83. Kortilla K, Pentii OM, Auvinen J. Comparison of i.m. lysine acetyl-salicylate and oxycodone in the treatment of pain after operation. Br J Anaesth 1980; 52 (6): 613-7.
84. Tamisto T, Tigerstedt I, Kortilla K. Comparison of lysine acetylsalicylate and oxycodone in postoperative pain following upper abdominal surgery. Ann Chir Gynaecol 1980; 59 (6): 287-92.
85. Angle P, Walsh V. Pain relief after caesarean section. Tech Reg Anesth Pain Manage 2001; 5 (1): 36-40.
86. Edward JE, Moore RA, McQuay HJ. Single-dose oxycodone and oxycodone plus paracetamol for acute postoperative pain. Cochrane Database Syst Rev 2000; 4: C0002763.
87. Palangio MS, Wideman GL, Keffer M, Landau M, Morris E, Doyle RT, et al. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of postoperative obstetric and gynaecologic pain. Clin Ther 2000; 22(5): 600-613.
88. Curtis GB, Johnson GH, Clark P, Taylor R, Brown J, O'Callaghan R, et al. Relative potency of controlled-release oxycodone and controlled-release morphine in a postoperative pain model. Eur J Clin Pharmacol 1999; 55: 425-9.
89. Levy MH. Advancement of opioid analgesia with controlled-release Oxycodone. Eur J Pain 2001; 5 (Supl. A): 113-6.
90. Bonica JJ Postoperative pain. In: Bonica JJ, ed. The management of pain. 2nd ed. Philadelphia: Lea and Febiger, 1990. p. 462.
91. American Pain Society. Principles of Analgesic Use in the Treatment of Acute pain and Cancer Pain. 4a ed. Glenview, IL: American Pain Society, 1999.
92. Palangio MS, Morris E, Doyle RT, Dornseif BE, Valente TJ. Combination hydrocodone and ibuprofen versus combination oxycodone and acetaminophen in the treatment of moderate or severe acute low back pain. Clin Ther 2002; 24 (1): 87-99.
93. Reuben SS, Connelly NR, Maciolek H. Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 1999; 88: 1286-91.
94. Muittari P, Kirvëla O. The safety and efficacy of intrabursal oxycodone and bupivacaine in analgesia after shoulder surgery. Reg Anesth 1998; 23(5): 474-8.
95. Cheville A, Chen A, Oster G, McGarry L, Narcessian E. A randomized trial of controlled-release Oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. The Journal of Bone & Joint Surgery 2001; 83-A(4): 572-6.
96. Stoll AL, Rueter S. Treatment augmentation with opiates in severe and refractory major depression. Am J Psych 1999; 156 (12): 2017.
97. Caldwell JR, Hale ME, et al. Treatment of osteoarthritis pain with controlled-release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflamatory drugs: a double blind randomized multicenter, placebo controlled trial. J Rheumatol 1999; 26: 862-9.
98. Sanford HR, Roy M, Fleischmann, et al. Around the clock, controlled release oxycodone therapy for osteoarthritis related pain. Arch of Internal Med 2000; 160 (6): 853-60.
99. Ytterberg SR, Maren L, Sharon R. Codeine and oxycodone use in patients with chronic rheumatic disease pain. Arthritis and Rheumatism 1998; 41 (9): 1603-12.
100. Cooper SA, Precheur H, Rauch D, et al. Evaluation of oxycodone and acetaminophen of postoperative dental pain. Oral Surg Oral Med and Oral Pathol 1980; 50 (6): 496-501.
101. Pöiyha R. Opioids in anaesthesia: a questionnaire survey in Finland. Eur J Anaesthesiol 1994; 11: 21-30.
102. Stambaugh J, Drew J. The combination of ibuprofen and oxycodone/acetaminophen in the management of chronic cancer pain. Clin Pharmacol Ther 1988; 44 (6): 665-9.
103. Kalso E. Pharmacocinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1995; 39(2): 214-5.
104. Olkkola K, Hamunen K, Seppala T, Maunuksela EL. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children. Br J Clin Pharmacol 1994; 38 (1): 71-6.
105. Elliot SC, Miser AW, Dose AM, et al. Epidemiologic features of pain in pediatric cancer patients. A cooperative community based study. Clin J Pain; 7: 263-8.
106. Kokki H, Hendolin H. Comparison of spinal anaesthesia with epidural anaesthesia in paediatric surgery. Acta Anaesth Scand 1995; 39 (7): 896-900.
107. Sharar SR, Carrougher GJ, Selzer K, O'Donnell F, Vavilala MS. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil 2002; 23(1): 27-31.
108. Edwards WT. Optimizing opioid treatment of postoperative pain. J. Pain Symptom manage 1990; 5: S24-36.
109. Hasselström J, Eriksson S, Persson A, Rane A, Svensson JO, Säwe J. The Metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990; 29: 289-97.
110. Pöyhiä R, Kalso E, Seppala T. Pharmacodynamic interactions of Oxycodone and amitriptyline in healthy volunteers. Curr Res Ther 1992; 51: 739-49.
111. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639-46.
112. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996; 12 (3): 182-9.
113. Ripamonti C, Bruera E. CNS adverse effects of opioids in cancer patients. Guidelines for treatment. CNS Drugs 1997; 8 (1): 21-37.
114. Bruera E, Chadwick S, Weinlick A, et al. Delirium and seycodonevere sedation in patients with terminal cancer. Cancer Treat Rep 1987; 71(7/8): 87-8.
115. Saarialho-Kere U, Mattila MJ, et al. Psychomotor, respiratory and neuroendocrinological effects of a Mu-opioid receptor agonist (Oxycodone) in healthy volunteers. Pharmacol Toxicol 1989; 65: 252-7.
116. Porter J, Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980; 302(2): 123.
117. Dunbar SA, Katz NP. Chronic opioid therapy for non-malignant pain in patients with a history of substance abuse: report of 20 cases. J Pain Symptom Manage 1996; 11 (3): 163-71.
118. Maruta T, Swanson DW. Problems with the use of Oxycodone compound in patients with chronic pain. Pain 1981; 11: 389-96.
119. Kim P, Maree T, et al. Single-dose and steady state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52 (5): 487-95.
120. Twycross RG. Opioid analgesics in cancer pain: current practice and controversies. Cancer Surg 1988; 7: 29-53.
121. Anks GW. Opioid analgesics in the management of pain in patients with cancer: A review. Palliat Med 1987; 1: 1-25.
122. Hardy JC, Lee SW, Wilson CG. Intranasal drug delivery by spray and drops. J Pharm Pharmacol 1985; 37: 294-7.
123. Plummer JL, Cmielewiski PL, Reynolds GD, Gourlay GK, Cherry DA. Influence of polarity on dose-response relationships of intrathecal opioids in rats. Pain 1990; 40: 339-47.
124. Morrison JD, Loan WB, Dundee JW. Comparison of the efficacy of fourteen preparations in the relief of postoperative pain. BMJ 1971; 3: 287-90.
125. Weinberg DS, Inturrisi CE, Reidenberg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther 1988; 45: 355-42.
126. Pöiyä R, Seppala T, et al. The pharmacokinetics and metabolism of Oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 1992; 33: 617-21.
127. Bezinger D, Kaiko R, Miotto J, Fitzmartin R, Reder R. Differential effects of food on the bioavailability of controlled realease oxycodone tablets and immediate release oxycodone solution. J Pharmaceutical Sci 1996; 58 (4): 407-10.
128. Hasselstrom J, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990; 29: 289-97.
129. Portenoy RK. Opioid and adjuvant analgesics. Pain 1999: 3-18.
130. Pereira J, Lawlor P, Vigano A, Dorgan M, Bruera E. Equianalgesic dose ratios for opioids: a critical review and proposals for long-term dosing. J Pain and Sympt Management 2001; 22 (2): 672-87.
131. Suresh K, et al. Equianalgesia Demystified. Palliative Medicine Secrets. Ed. Hanley and Belfus. 1999. p. 97-102.
132. De Stoutz ND, Bruera E, Suárez M. Opioid rotation for toxicity reduction in terminal patients. J Pain Symptom Manage 1995; 10: 378-84.
133. Gebhardt R, Kinney MA. Conversion from intrathecal morphine to oral methadone. Regional Anesthesiology Pain Medicine 2002; 27(3): 319-21.
134. Bruera E, et al. Randomized, double blind cross over trial comparing safety and efficacy of oral controlled release oxycodone with controlled release morphine in patients with cancer pain. J Clin Oncol 1998; 16 (10): 3222-9.
135. Kaplan R, Parris C, Citron ML, et al. Comparison of controlled-release and immediate-release Oxycodone tablets in patients with cancer pain. J Clin Oncol 1998; 16: 3230-7.
136. Hale ME, Fleischman R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin J Pain 1999; 15: 179-83.
137. Silvast M, Rosenberg P, Sepällä N, Pitkänen M. Comparison of analgesico efficacy of oxycodone and morphine in postoperative intravenous patient controlled analgesia. Acta Anaesthesiol Scand 1998; 42: 576-80.